mat2a.

MAT2A inhibitor 2 is an inhibitor of methionine adenosyltransferase 2A (MAT2A).

MAT2A inhibitor 4 is an inhibitor of the catalytic subunit of methionine S-adenosyltransferase-2, which is used in cancer research.

MAT2A inhibitor 1 is an inhibitor of methionine adenosyltransferase 2A (MATA2) (IC50 < l00 nM).

MAT2A-IN-18 (Compound 15) is an inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC50 of 50 nM or less.

MAT2A-IN-20 (Compound A49) is an inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC50 of ≤50 nM. It also inhibits human UGT1A1 with an IC50 of 28.45 μM. Additionally, MAT2A-IN-20 exhibits antitumor activity in mouse models.

MAT2A-IN-19 (Compound I-3) is an inhibitor of methionine adenosyltransferase 2A (MAT2A), with an IC50 of 32.93 nM.

MAT2A-IN-16 is a MAT2A inhibitor that effectively suppresses the proliferation of MTAP- -HCT-116 cells, with an IC50 value of 20 nM.

MAT2A-IN-21 (compound 28) is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A), with an IC50 of 49 nM. It selectively inhibits cancer cells with MTAP deficiency.

MAT2A-IN-17 is a potent inhibitor of MAT2A, with an IC50 of less than 100 nM. MAT2A-IN-17 is applicable in cancer research.

MAT2A-IN-24 (Compound 9) is an inhibitor of methionine adenosyltransferase 2a (MAT2a), with an IC50 value of 20 nM for MAT2a inhibition and an antiproliferative IC50 value of 10 nM for HAP1MTAP–/– cells. MAT2A-IN-24 is applicable in the research of tumor diseases associated with MTAP deficiency.

MAT2A inhibitor 3 can be used in the cancer research. MAT2A inhibitor 3 is a inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC 50 of <200 nM [1].

MAT2A-IN-4 can be used for the cancer research that is an inhibitor of methionine adenosyltransferase 2A (MAT2A)[1].

MAT2A-IN-5, a potent inhibitor of MAT2A, effectively targets the abnormally elevated expression of MAT2A found in various tumor types such as gastric, colon, liver, and pancreatic cancers. By reducing the proliferative activity of MTAP-deficient cancer cells, MAT2A-IN-5 exhibits potential in cancer research applications [1].

MAT2A-IN-7, a potent inhibitor of the enzyme MAT2A, demonstrates efficacy in targeting the abnormally elevated expression of MAT2A observed in gastric, colon, liver, and pancreatic cancers. Furthermore, MAT2A-IN-7 effectively reduces the proliferative activity specifically in MTAP-deficient cancer cells, thus highlighting its potential for cancer research applications [1].

MAT2A-IN-6 is a potent inhibitor of MAT2A that reduces the proliferative activity of MTAP-deficient cancer cells, demonstrating significant research potential in cancer diseases.

MAT2A-IN-2, a potent inhibitor of MAT2A, shows potential for cancer disease research.

MAT2A-IN-3, a potent MAT2A inhibitor, suppresses the proliferative activity of MTAP-deficient cancer cells and shows potential for cancer research [3=c₁(c(c(c(c(c₁cl)O)O)O)I)c₂c(NC(c(n₂)C(F)(F)F)Cl)=O].

MAT2A-IN-1 is a potent inhibitor of MAT2A, displaying proliferative activity in MTAP-deficient cancer cells. MAT2A is highly expressed in several tumours, including gastric, colon, liver, and pancreatic cancers. MAT2A-IN-1 shows significant potential for cancer research.

MAT2A-IN-9, a 2-oxoquinazoline derivative, is a potent MAT2A (methionine adenylyltransferase 2A) inhibitor.MAT2A-IN-9 has antitumor activity for the treatment of lymphomas and solid tumors.

MAT2A-IN-10 (Compound 28), an orally active inhibitor of MAT2A, exhibits an IC50 of 26 nM and is utilized in cancer research [1].

MAT2A Allosteric Inhibitor 1, also known as Compound 5, is a selective inhibitor of methionine adenosyltransferase (MAT) demonstrating potent activity with an IC50 value of 6.8 nM [1].

MAT2A Allosteric Inhibitor 2 is a potent, selective inhibitor exhibiting an IC50 of 5 nM and demonstrates nanomolar efficacy (IC50 = 5 μM) in proliferation assays utilizing the MTAP - - cell line [1].

MAT2A-IN-8 is an inhibitor of MAT2A.

MAT2A-IN-13 is a potent, orally active methionine adenosyltransferase 2A (MAT2A) inhibitor with a favorable pharmacokinetic profile, demonstrating in vivo efficacy in an HCT-116 MTAP-deleted xenograft model and potential use in MTAP-deleted tumors treatment research [1].